Passive immunization against tumor necrosis factor partially abrogates interleukin 2 toxicity

Area of Science:

• Immunology
• Cancer Research
• Pharmacology

Background:

• Interleukin-2 (IL-2) is an immunotherapy with antitumor properties but is limited by significant toxicity.
• Tumor necrosis factor (TNF) is a pro-inflammatory cytokine implicated in various biological processes, including immune responses and toxicity.

Purpose of the Study:

• To investigate the role of TNF in mediating IL-2 toxicity.
• To determine if inhibiting TNF affects the antitumor efficacy of IL-2.
• To evaluate strategies for improving the therapeutic index of IL-2 in cancer treatment.

Main Methods:

• Passive immunization using neutralizing antibodies against TNF in both non-tumor-bearing and tumor-bearing mouse models.
• Administration of varying doses of IL-2 to assess toxicity thresholds.
• Evaluation of IL-2's antitumor effects against pulmonary metastases in the presence of TNF inhibition.

Main Results:

• Mice treated with anti-TNF antibodies tolerated significantly higher doses of IL-2 before experiencing lethal toxicity.
• The antitumor efficacy of IL-2 against pulmonary metastases was preserved in mice receiving concurrent anti-TNF treatment.
• Increased IL-2 administration, enabled by TNF blockade, led to an improved antitumor response compared to control groups.

Conclusions:

• TNF is a key mediator of IL-2-induced toxicity.
• Inhibition of TNF minimally impacts, and may even enhance, the antitumor effects of IL-2.
• Targeting TNF represents a promising strategy to enhance the therapeutic index and clinical utility of IL-2 in cancer therapy.